EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Liver metastasis ablation combined with PD ‐1 inhibitors improves immunotherapy efficacy: A multicenter cohort study

Dengyao Liu, Bingchen Xu, Dongcun Huang, Zhanguo Sun, Tao Zhu, Pan Hu, Dechao Jiao, Fujun Zhang iD, Letao Lin iD

International Journal of Cancer · 15.08.2026 · 159 (4) · 951-959

DOI: 10.1002/ijc.70462 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, online erschienen am 25.03.2026. Verfasst von Dengyao Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Minimally Invasive Intervention, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Can…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Immunotherapy, Liver Neoplasms. Die Arbeit nennt 25 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Regional Science and Technology Support Xinjiang Project, Tianshan Talent Training Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with liver metastases generally have poorer outcomes following immunotherapy compared with those without liver involvement, and whether local ablation can enhance systemic antitumor immunity remains unclear. In this retrospective study, we evaluated the efficacy of combining ablation with PD‐1 inhibitor therapy versus PD‐1 inhibitor monotherapy in patients with liver metastases. A total of 1337 patients who received PD‐1 inhibitors with or without ablation between January 2017 and September 2022 at three institutions were reviewed. After propensity score matching, 234 patients were included, with 117 in the combination group and 117 in the monotherapy group. The combination group achieved significantly longer median overall survival (20.13 vs. 13.83 months, p = .023) and progression‐free survival (12.73 vs. 5.20 months, p < .001). Progression of extrahepatic lesions was markedly lower in the combination group than in the monotherapy group (35.9% vs. 66.7%, p < .001). Treatment‐related adverse events were common in both groups, with a higher frequency of grade 1–2 events such as transaminase elevation, fever, nausea, vomiting, and abdominal pain in the combination group, while the incidence of grade 3–4 toxicities was comparable between groups and no treatment‐related deaths occurred. Multivariate Cox regression confirmed treatment modality as an independent prognostic factor for survival ( p < .001). These findings suggest that ablation of intrahepatic lesions may alleviate systemic immunosuppression and augment the efficacy of immunotherapy. The combination of ablation and PD‐1 inhibitors represents a promising therapeutic approach for patients with liver metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsImmunotherapyLiver NeoplasmsAgedFemaleHumansMaleMiddle AgedCombined Modality TherapyProgrammed Cell Death 1 ReceptorRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

CTablationimmunotherapyliver metastasistreatment outcome

Substanzen

Immune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Minimally Invasive Intervention, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis an…
  • Department of Interventional Radiology, Xinjiang Key Laboratory of Translational Biomedical Engineering Research, Tumor Hospital Affiliated to Xinjiang Medical University, China.
  • Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

ORCID-Profile: Fujun Zhang, Letao Lin

Förderung

  • National Natural Science Foundation of China
  • Regional Science and Technology Support Xinjiang Project
  • Tianshan Talent Training Program

Zitieren

APA

Liu, D., Xu, B., Huang, D., Sun, Z., Zhu, T., Hu, P., Jiao, D., Zhang, F., & Lin, L. (2026). Liver metastasis ablation combined with PD ‐1 inhibitors improves immunotherapy efficacy: A multicenter cohort study. International Journal of Cancer, 159(4), 951-959. https://doi.org/10.1002/ijc.70462

Vancouver

Liu D, Xu B, Huang D, Sun Z, Zhu T, Hu P, et al. Liver metastasis ablation combined with PD ‐1 inhibitors improves immunotherapy efficacy: A multicenter cohort study. International Journal of Cancer. 2026;159(4):951-959. doi:10.1002/ijc.70462

BibTeX
@article{Liu2026,
  author = {Liu, Dengyao and Xu, Bingchen and Huang, Dongcun and Sun, Zhanguo and Zhu, Tao and Hu, Pan and Jiao, Dechao and Zhang, Fujun and Lin, Letao},
  title = {Liver metastasis ablation combined with PD ‐1 inhibitors improves immunotherapy efficacy: A multicenter cohort study},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {4},
  pages = {951--959},
  doi = {10.1002/ijc.70462}
}
Kostenlos starten →